10 February 2018 : Laboratory Research
Baculoviral IAP Repeat Containing 6 (BIRC6) Is a Predictor of Prognosis in Prostate Cancer
Wenzhen Zhuang1ABC, Cuixia Zhang1CD, Furong Hao2DEF, Xicai Sun3FGDOI: 10.12659/MSM.904052
Med Sci Monit 2018; 24: LBR839-845
Abstract
BACKGROUND: Baculoviral IAP repeat containing 6 (BIRC6), a member of the inhibitors of apoptosis protein (IAP) family, has been reported to be correlated with oncogenesis. The aim of this study was to investigate the prognostic significance of BIRC6 in prostate cancer, as well as its effects on prostate cancer cell lines.
MATERIAL AND METHODS: BIRC6 protein expression was investigated in 112 prostate cancer tissues and 86 benign prostate disease tissues using immunohistochemistry. Overall survival was assessed by Kaplan-Meier analysis with log-rank test. To evaluate the prognostic significance of BIRC6, Cox regression models were applied. The effects of BIRC6 on human prostate cancer cells were confirmed via small interfering RNA.
RESULTS: BIRC6 protein levels were significantly higher in prostate cancer tissues than that in benign prostate tissues (P<0.001). High BIRC6 expression was associated with advanced pathological stage (P=0.011) and positive metastasis (P=0.036). In addition, patients with high BIRC6 expression had worse survival than those with low expression (Log-rank test, P=0.002). Multivariate analysis demonstrated that BIRC6 expression was an independent prognostic factor for prostate cancer (HR=2.771, 95%CI=1.427–5.378, P=0.003). Furthermore, cell experiments suggested that BIRC6 knockdown inhibits cell proliferation and promote apoptosis (P<0.05 for all).
CONCLUSIONS: Upregulated BIRC6 predicts aggressive clinical characteristics and poor prognosis in prostate cancer patients. BIRC6 can regulate prostate cancer cell proliferation and apoptosis, which may be a potential therapeutic target.
Keywords: Betula, Prostatic Neoplasms
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...Med Sci Monit In Press; DOI: 10.12659/MSM.943884
08 Mar 2024 : Clinical Research
Evaluation of Foot Structure in Preschool Children Based on Body MassMed Sci Monit In Press; DOI: 10.12659/MSM.943765
15 Apr 2024 : Laboratory Research
The Role of Copper-Induced M2 Macrophage Polarization in Protecting Cartilage Matrix in OsteoarthritisMed Sci Monit In Press; DOI: 10.12659/MSM.943738
07 Mar 2024 : Clinical Research
Knowledge of and Attitudes Toward Clinical Trials: A Questionnaire-Based Study of 179 Male Third- and Fourt...Med Sci Monit In Press; DOI: 10.12659/MSM.943468
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952